James Evans

Also affiliated with Revolution Medicines (United States), Kingston Hospital

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy”.

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Nature(2024)10.1038/s41586-024-07205-6

N/A

4.2DataRank · unranked

326 citations

Bianca J. Lee, Jingjing Jiang, Aidan C.A. Tomlinson, Kyle J. Seamon, Alessia Mira +48 more

Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth

Nature Chemical Biology(2021)10.1038/s41589-021-00843-1

N/A

0DataRank · unranked

2 citations

Jacob A. Boyer, G. Leslie Burnett, Arun P. Thottumkara, Nidhi Tibrewal, Stacy Wilson +21 more

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer

Nature Communications(2024)10.1038/s41467-024-50063-z

N/A

0DataRank · unranked

35 citations

Philip H. Choi, Yu Chi Yang, Jacob A. Boyer, Adele Whaley, Priya Pancholi +16 more

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

UNC Libraries(2024)10.17615/1fr6-tv06

N/A

0DataRank · unranked

0 citations

Nicole Nasholm, Chiara Ambrogio, Anthony N. Milin, Yang Liu, Elsa Quintana +48 more